These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 19527463

  • 1. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.
    Sakai Y, Sakai S, Otsuka T, Ohno D, Murasawa T, Munakata K, Mizuno K.
    Ther Apher Dial; 2009 Jun; 13(3):179-85. PubMed ID: 19527463
    [Abstract] [Full Text] [Related]

  • 2. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 3. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with rheumatoid arthritis.
    Kitagaichi M, Kusaoi M, Tsukahara T, Murayama G, Nemoto T, Sekiya F, Kon T, Ogasawara M, Kempe K, Yamaji K, Tamura N, Tsuda H, Takasaki Y.
    Transfus Apher Sci; 2016 Oct; 55(2):225-232. PubMed ID: 27475801
    [Abstract] [Full Text] [Related]

  • 5. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis.
    Onuma S, Yamaji K, Kempe K, Ogasawara M, Ogawa T, Yang K, Kanai M, Tsuda H, Takasaki Y.
    Ther Apher Dial; 2006 Oct; 10(5):404-11. PubMed ID: 17096694
    [Abstract] [Full Text] [Related]

  • 6. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 7. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 8. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
    Sanmartí R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N, Rodriguez-Cros JR, Erra A, Reina D, Gratacós J.
    Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
    [Abstract] [Full Text] [Related]

  • 9. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 10. Ultrasound evaluation of the effects of leukocytapheresis on rheumatoid arthritis.
    Yoshida S, Takeuchi T, Maeda Y, Kimura Y, Hata K, Hiramatsu Y, Shoda T, Makino S, Hanafusa T, Shibahara N.
    Ther Apher Dial; 2014 Oct; 18(5):509-14. PubMed ID: 24251814
    [Abstract] [Full Text] [Related]

  • 11. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y, Youssef SS, El Gaafary M.
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [Abstract] [Full Text] [Related]

  • 12. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S.
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [Abstract] [Full Text] [Related]

  • 13. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE.
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [Abstract] [Full Text] [Related]

  • 14. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [Abstract] [Full Text] [Related]

  • 15. A multicenter study of leukocytapheresis in rheumatoid arthritis.
    Ueki Y, Sagawa A, Tanimura K, Yamada A, Yamamoto K, Tsuda H, Tohma S, Suzuki K, Tominaga M, Kawabe Y, Mine M, Honda S, Tsukano M, Nakamura T, Hidaka T, Eguchi K.
    Clin Exp Rheumatol; 2007 May; 25(6):810-6. PubMed ID: 18173913
    [Abstract] [Full Text] [Related]

  • 16. Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis.
    Eguchi K, Saito K, Kondo M, Hidaka T, Ueki Y, Tanaka Y, LCAP Investigators in Kyushu College of Rheumatology (LIKCR).
    Mod Rheumatol; 2007 May; 17(6):481-5. PubMed ID: 18084700
    [Abstract] [Full Text] [Related]

  • 17. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J.
    Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
    [Abstract] [Full Text] [Related]

  • 18. Recruitment of immature neutrophils in peripheral blood following leukocytapheresis therapy for rheumatoid arthritis.
    Okawa-Takatsuji M, Nagatani K, Nakajima K, Itoh K, Kano T, Nagashio C, Takahashi Y, Aotsuka S, Mimori A.
    J Clin Apher; 2007 Aug; 22(6):323-9. PubMed ID: 18095302
    [Abstract] [Full Text] [Related]

  • 19. A case report of leukocytapheresis for refractory leg ulcers complicated with rheumatoid arthritis.
    Itoh Y, Takeshita Y, Ozawa Y, Tohma S, Umemura S.
    Ther Apher Dial; 2006 Oct; 10(5):419-24. PubMed ID: 17096696
    [Abstract] [Full Text] [Related]

  • 20. Leukocytapheresis Therapy for Rheumatoid Arthritis: Results Compared with Control Trial.
    Huang J, Wang Q, Cheng Y, Chen Y, Gao M, Yang F, Mu B, Zhou R, Huang C.
    Altern Ther Health Med; 2020 Jul; 26(4):36-42. PubMed ID: 31221941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.